Skip to content
TrialMatch
Sign up
Recruiting Phase 1

Safety and Efficacy Study of BAFF-R CAR-T Cells in Adult Subjects With CD19-Negative Relapsed or Refractory B-Cell Lymphoma

Create a profile to match View the full record on ClinicalTrials.gov

About this study

The purpose of this study is to evaluate the safety and tolerability of BAFF-R CAR-T Cells in Adult Subjects with CD19-Negative relapsed or refractory B-Cell Lymphoma.

Condition
B-cell Lymphoma
Tested
BAFF-R CAR-T cells
Sponsor
Jiangsu Topcel-KH Pharmaceutical Co., Ltd.

Who can join

Age
18 years and older
Sex
All sexes
Healthy volunteers
Not accepted

Inclusion 18

  • Minimum age: 18 years
  • Study condition: B-cell Lymphoma
  • 1\. Subjects voluntarily participate in clinical research and sign informed consent.
  • Subjects with CD19-negative relapsed or refractory B-cell lymphoma: a) failure to achieve CR after 6 cycles, or PR after 3 cycles, of first-line therapy, or achieve CR after first-line therapy but relapse within 12 months; b) achieve CR after systemic treatment, but are refractory or relapsed, and no plan to transplant, or prepare for transplantation but cannot meet transplantation criteria after second-line therapy; c) not achieve CR after at least two courses of second-line treatment (including autologous stem cell transplantation).
  • 3\. Expected survival ≥ 3 months.
  • 4\. BAFF-R expression are detected on tumor cells of subjects by flow cytometry or immunohistochemistry.
  • 5\. ECOG score ≤ 2.
  • 6\. Subjects with adequate organ functions prior to enrollment, meet the following laboratory values:
  • Renal function: serum creatinine ≤ 1.5 × ULN or estimated glomerular filtration rate (eGFR) ≥ 60 mL/min/1.73 m²
  • Hepatic function: Serum alanine aminotransferase (ALT) ≤ 5 × age-specific ULN and total bilirubin ≤ 2.0 mg/dL, except in subjects with Gilbert-Meulengracht syndrome. If total bilirubin ≤ 3.0 × ULN and direct bilirubin ≤ 1.5 × ULN, subjects with Gilbert-Meulengracht syndrome are included.
  • Pulmonary reserve: ≤ Grade 1 dyspnea and oxygen saturation \>95% on room air.
  • 7\. Stable hemodynamics and left ventricular ejection fraction (LVEF) ≥ 45 % assessed by echocardiography or multi-gated radionuclide angiography (MUGA).
  • 8\. Adequate bone-marrow reserve without blood transfusion as defined by:
  • Absolute neutrophil count (ANC) ≥ 1 x 10\^9/L.
  • Absolute lymphocyte count (ALC) ≥ 0.1 x 10\^9/L.
  • Platelets ≥ 50 x 10\^9/L.
  • Hemoglobin \>80g/L.
  • 9\. In the investigator's judgment, subjects' general condition and all biochemical values are either normal or sufficiently compensated to receive lymphodepletion and CAR-T cell therapy.

Exclusion 8

  • 1\. Women who are pregnant or breastfeeding, or planned pregnancy within 6 months.
  • 2\. Infectious disease(HIV, Active Tuberculosis ect.).
  • 3\. Active infection: hepatitis B, hepatitis C.
  • 4\. Abnormal vital signs or refuse to receive examination.
  • 5\. Subjects with psychiatric or psychological disorders are unable to complete treatment or efficacy assessment.
  • 6\. History of severe hypersensitivity or known hypersensitivity to IL-2.
  • 7\. Systemic or local severe infection requiring antimicrobial therapy.
  • 8\. Significant dysfunction of vital organs (heart, lung, brain, kidney, etc.), or in the investigator's judgment, subjects are unable to be enrolled with any other condition.

Where

1 site, 1 recruiting

Suzhou Hongci Hematology Hospital

Suzhou, China

Recruiting

Contact

Potential match only. Final eligibility is determined by the study team.